Keywords: Sucampo Pharma, Takeda, Lubiprostone, OBD, bowel dysfunction, Ph III

Sucampo’s OBD drug meets Ph III endpoint

Article | 02 February 2012

USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) and Japanese drug major Takeda Pharmaceuticals’ (TYO: 4502) US subsidiary revealed that lubiprostone met the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Sucampo

Takeda Pharmaceuticals

Go to company listing

Related Drugs

Lubiprostone

Go to drug listing